Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

stock market

Cano Health separates leadership roles following board member exits

The news comes just days after three former board members penned an open letter to all Cano Health shareholders discussing their concerns about the company.

Supreme Court halts restrictions on abortion pill

The Supreme Court has stepped in to block a Texas-based federal judge’s order that pulled back the approval of mifepristone.

Thumbnail

Outcome Health execs convicted in $1B fraud scheme

Three former executives from Outcome Health, a health technology startup company based in Chicago, have been convicted by a jury in a fraud scheme amounting to approximately $1 billion.

Thumbnail

DOJ to appeal abortion pill case to Supreme Court

“The Justice Department strongly disagrees with the Fifth Circuit’s decision in Alliance for Hippocratic Medicine v. FDA to deny in part our request for a stay pending appeal,” Attorney General Merrick Garland said April 13.

Thumbnail

Political climate leads to loss of labor and delivery services

Bonner General Health, based in Sandpoint, Idaho, alerted the public about the upcoming discontinuation of labor and delivery services.

SCAI blasts Medicare payment cuts to cardiology, asks members to take action

The group hopes its members can increase congressional support of a new bill introduced in the House. 

Thumbnail

Sanofi’s $2.9B acquisition of Provention Bio delayed by FTC review

According to Sanofi, it has withdrawn and refiled its premerger notification and report form with the FTC to give the agency more time to review the deal.

cardiovascular risk infectious disease hospitalization

CMS proposes 2.8% rate increase for inpatient payments in 2024

CMS is also proposing that rural emergency hospitals be designated graduate medical education training sites, enabling more medical students to train in those areas.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup